Medifast Intrinsic Value Calculator – Is It Too Late to Invest in Medifast,?
December 12, 2023
🌥️Trending News
When it comes to investing in Medifast ($NYSE:MED), Inc., the question many potential investors have is whether or not it is too late to get in. The answer depends on a number of factors and the individual investor’s risk tolerance. The company’s primary focus is providing weight-loss solutions through diet plans, meal replacement products and lifestyle coaching.
In addition, the company has seen solid growth in its customer base and has launched several innovative products that have been well-received. At the same time, investors should also take into account potential risks associated with Medifast, such as competition from other diet programs, changes in customer preferences and economic conditions.
Share Price
It appears that it may be too late to invest in Medifast, Inc. On Tuesday, the company’s stock opened at $67.2 and closed at $65.8, representing a decrease of 2.6% from the previous closing price of 67.5. As such, the market sentiment towards Medifast is currently bearish. Nevertheless, investors may still have a chance to hop on the Medifast train if the market sentiment starts to turn bullish again. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medifast. More…
| Total Revenues | Net Income | Net Margin |
| 1.22k | 119.9 | 9.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medifast. More…
| Operations | Investing | Financing |
| 188.87 | -59.38 | -86.22 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medifast. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 320.02 | 126.98 | 17.72 |
Key Ratios Snapshot
Some of the financial key ratios for Medifast are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.2% | 9.4% | 12.3% |
| FCF Margin | ROE | ROA |
| 14.3% | 49.6% | 29.4% |
Analysis – Medifast Intrinsic Value Calculator
At GoodWhale, we have been analyzing MEDIFAST’s financials and came up with an intrinsic value of around $154.2 for its share, calculated by our proprietary Valuation Line. This is much higher than its current price of $65.8, making the stock a great buy opportunity. We believe that MEDIFAST is currently undervalued by 57.3%, making it a highly attractive investment for strategic investors. Medifast“>More…
Peers
The company operates through four segments: Weight Management, Healthy Living, Professional Services, and Corporate. Medifast Inc has a wide range of competitors including Terminix Global Holdings Inc, WW International Inc, and Apiam Animal Health Ltd.
– Terminix Global Holdings Inc ($NASDAQ:WW)
Organifi is a wellness company that offers a line of nutritional supplements and other health-related products. The company was founded in 2013 and is headquartered in San Diego, California. Organifi’s products are sold online and through a network of independent distributors. The company’s flagship product is a green powder drink mix that contains a blend of superfoods, vitamins, and minerals. Organifi also sells protein powders, probiotics, and other health supplements.
As of 2022, Organifi had a market capitalization of $305.47 million and a return on equity of -20.95%. The company’s products are designed to improve overall health and wellness, and its flagship green powder drink mix is a popular choice among health-conscious consumers. While Organifi’s return on equity is negative, this is largely due to the company’s heavy investment in marketing and product development. Over the long term, Organifi should be able to generate strong profits as it grows its customer base and expands its product offerings.
– WW International Inc ($ASX:AHX)
Apiam Animal Health Ltd is a company that produces animal health products. Its market cap is 127.53M as of 2022 and its ROE is 4.91%. The company’s products include vaccines, antibiotics, and other health products for animals.
Summary
Medifast, Inc. is a health and wellness company that manufactures and sells weight-management and health products through multiple channels. As an investment, Medifast has seen mixed performance in terms of stock price and market capitalization over the past five years. The company is currently trading at a lower than average price-to-earnings ratio, suggesting that it may be undervalued and attractive to investors.
The company also has a well-diversified product portfolio and strong customer loyalty. Overall, Medifast appears to be an attractive investment opportunity for those looking for a value stock.
